OraSure Technologies, Inc.

387 articles about OraSure Technologies, Inc.

• OraSure Technologies, Inc. Prices Underwritten Offering of Common Stock - June 03, 2020

  6/3/2020

  OraSure Technologies, Inc. announced the pricing of an underwritten offering of 8,000,000 shares of its common stock at a price of $11.00 per share.

• OraSure Technologies, Inc. Announces Proposed Public Offering of Common Stock - Jun 01, 2020

  6/1/2020

  OraSure Technologies, Inc. announced it has commenced an underwritten public offering of 8,000,000 shares of its common stock.

• OraSure Technologies, Inc. Announces Purchase of UrSure, Inc.

  5/29/2020

  OraSure Technologies, Inc., a leader in point of care diagnostic tests and specimen collection and stabilization devices, and microbiome laboratory and analytical services, announced that it has entered into a definitive agreement to acquire privately owned UrSure, Inc. for cash.

• OraSure Technologies Appoints Lelio Marmora to Board of Directors

  5/29/2020

  OraSure Technologies, Inc., a leader in point of care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced the appointment of Lelio Marmora as a member of the Company’s Board of Directors effective June 1, 2020.

• OraSure Technologies to Present at the Jefferies 2020 Healthcare Conference

  5/26/2020

  OraSure Technologies, Inc., a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and analytical services, announced that Dr. Stephen S. Tang, Ph.D., President and CEO, will speak to the investment community at the Jefferies 2020 Healthcare Conference.

• OraSure’s OMNIgene®·ORAL Kit Included in EUA Granted to P23 Labs for At-Home Collection of Saliva Samples for SARS-CoV-2 Test

  5/22/2020

  OraSure Technologies, Inc., a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced that its OMNIgene®·ORAL saliva collection device was included in the U.S. Food and Drug Administration Emergency Use Authorization granted to P23 Labs.

• Diversigen Inc. Selected by Nom Nom™ as the Preferred Provider for Metagenomics and Microbiome Sequencing and Analysis Services

  5/22/2020

  Diversigen, Inc., a subsidiary of OraSure Technologies Inc., and Nom Nom™, a direct-to-consumer pet health brand, announced that Nom Nom has selected Diversigen as their preferred provider for metagenomics and microbiome sequencing and analysis services.

• OraSure Technologies to Present at the UBS Virtual Global Healthcare Conference

  5/15/2020

  OraSure Technologies, Inc., a leader in point of care diagnostic tests and specimen collection devices, announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the UBS Virtual Global Healthcare Conference.

• OraSure Technologies to Hold Virtual Annual Meeting of Stockholders on May 19, 2020

  5/14/2020

  OraSure Technologies, Inc., announced that its 2020 Annual Meeting of Stockholders will be a completely virtual meeting, conducted as a live webcast beginning at 10:00 a.m. EDT on Tuesday, May 19, 2020.

• OraSure Technologies, Inc. Consolidates Microbiome Services Subsidiaries

  5/12/2020

  OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that its Diversigen and CoreBiome subsidiaries have combined their microbiome service offerings under the Diversigen name. The rebrand highlights the combined companies’ unparalleled scientific bench

• OraSure Announces 2020 First Quarter Financial Results and Provides COVID-19 Update

  5/6/2020

  OraSure Technologies, Inc. announced its financial results for the three months ended March 31, 2020 and provided an update on COVID-19 activities.

• OraSure Technologies Appoints Lisa Nibauer as Infectious Disease Business Unit LeadBoard Change Also Announced

  5/5/2020

  OraSure Technologies, Inc., a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced that Lisa Nibauer has been appointed Executive Vice President, Business Unit Leader, Infectious Disease.

• DNA Genotek’s ORAcollect®·RNA kit included in EUA granted to Biocerna SARS-CoV-2 test

  5/4/2020

  DNA Genotek Inc., a leading provider of sample collection kits and end-to-end services and a wholly-owned subsidiary of OraSure Technologies, Inc., announced that its ORAcollect®·RNA kit was included as the collection device for anterior nares samples under a U.S.

• OraSure Technologies 2020 First Quarter Earnings Conference Call Invitation

  4/9/2020

  OraSure Technologies, Inc. has scheduled its regular earnings conference call covering 2020 first quarter financial results, updated financial guidance and certain business developments for 5:00 pm ET on Wednesday, May 6, 2020..

• OraSure Technologies Appoints David J. Shulkin, M.D. to Board of DirectorsOther Board Changes Also Announced

  4/8/2020

  OraSure Technologies, Inc., a leader in point of care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced the appointment of David J. Shulkin, M.D., as a member of the Company’s Board of Directors.

• 

  Biopharma Update on the Novel Coronavirus: April 8

  4/8/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 8, 2020.

• OraSure Technologies Receives BARDA Contract for Rapid Oral Fluid Pan-SARS-Coronavirus In-home Self-test

  4/6/2020

  OraSure Technologies, Inc. announced it has been awarded a $710,310 contract from the Biomedical Advanced Research and Development Authority, part of the Department of Health and Human Services, to develop a pan-SARS-coronavirus antigen rapid in-home self-test that uses oral fluid samples.

• OraSure Technologies to Present at the Raymond James 41st Annual Institutional Investors Conference

  2/26/2020

  OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the Raymond James 41st Annual Institutional Investors Conference.

• OraSure Announces 2019 Full Year and Fourth Quarter Financial Results

  2/19/2020

  OraSure Technologies, Inc. announced its financial results for the three months and year ended December 31, 2019.

• OraSure Technologies Earnings Conference Call Invitation2019 Fourth Quarter Earnings Conference Call Wednesday, February 19, 2020, 5:00 p.m. ET

  1/29/2020

  OraSure Technologies, Inc. has scheduled its regular earnings conference call covering 2019 fourth quarter financial results, updated financial guidance and certain business developments for 5:00 pm ET on Wednesday, February 19, 2020..